Several etiologic factors have been suggested for prostate cancer, including both genetic and environmental factors. Established risk factors include age, race, and family history. It is becoming more apparent that common polymorphisms that result in quantitative or qualitative functional differences in protein products play an important role in modifying disease risk. For prostate cancer, the most compelling hypothesis for increased cancer risk supports a hormonal involvement, which could include enzymes involved in the androgen metabolic pathway and gonadotrophins. Additionally, there is evidence suggesting that estrogen metabolites, as genotoxins, also increase risk for prostate cancer. In this study, we propose to systematically test the hypothesis that common genetic polymorphisms for enzymes that catalyze the synthesis and bioactivation of androgens and estrogen (CYP11A1, CYP17, CYP 19, HSD3B2, HSD17B1, HSD17B3, AKR1C3, SRD5A2), either individually or in combination, are risk factors for prostate cancer. In addition, we hypothesize that common genetic polymorphisms that catalyze the synthesis of catecholestrogens (CYP1A1 and CYP1B1), as well as enzymes that metabolically inactivate estrogens, catecholestrogens, or genotoxins generated from catecholestrogens (COMT, SULT1A1, the GSTs and NQO1), either individually or in combination, might also represent predisposing genetic risk factors for prostate cancer. This hypothesis will be tested in a case-control study that uses two sets of previously identified cases - those with a strong family history of prostate cancer (n=449 from 181 families) and those with a reported negative prostate cancer family history (n=500) - and a population-based control group (n=510). The controls have been extensively screened for prostate cancer by digital rectal examination, serum PSA measurement, transrectal sonographic imaging and when indicated, biopsy. At the conclusion of this project, we will have provided important insight into the potential role of a group of genes important in androgen and estrogen metabolism and generated hypotheses about how these interact in the etiology of prostate cancer. Additionally, by making pairwise comparisons among these three groups of subjects, we will be able to discern whether these common polymorphisms are more strongly associated with familial or sporadic prostate cancer, similarly associated with both or with neither. The overarching goal of this project is to identify genetic susceptibility factors of prostate cancer in order to improve our understanding of the etiology of this disease and potentially identify men at increased risk of developing the disease in whom prevention strategies might be targeted.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA091956-01
Application #
6542267
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-08-31
Project End
2006-07-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Guerrico, Anatilde Gonzalez; Hillman, David; Karnes, Jeffery et al. (2017) Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. J Circ Biomark 6:1849454417720151
Hearn, Jason W D; AbuAli, Ghada; Reichard, Chad A et al. (2016) HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 17:1435-1444
Spratt, Daniel E; Evans, Michael J; Davis, Brian J et al. (2015) Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res 75:4688-96
Lu, Ji; Lonergan, Peter E; Nacusi, Lucas P et al. (2015) The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol 193:690-8
Urban, Matthew W; Wang, Chenyi; Alizad, Azra et al. (2015) Complex background suppression for vibro-acoustography images. Ultrasonics 56:456-72
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Alshalalfa, Mohammed; Crisan, Anamaria; Vergara, Ismael A et al. (2015) Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 116:556-67
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Ahmed, Kamran A; Davis, Brian J; Mynderse, Lance A et al. (2014) Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol 9:171
Wu, Qiang; Kohli, Manish; Bergen 3rd, H Robert et al. (2014) Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther 13:1067-77

Showing the most recent 10 out of 206 publications